Compare Manulife Financial Corporation (MFC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs TG Therapeutics Inc — how do they compare? Manulife Financial Corporation trades at $43.84 (market cap $72.68B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Manulife Financial Corporation is far larger — about 9.5× TG Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MFC | TGTX | |
|---|---|---|
Market Cap | $72.68B | $7.64B |
Sector | Financials | Health |
52-Week High | $44.77 | $59.06 |
52-Week Low | $30.06 | $26.94 |
Enterprise Value | $67.84B | $7.84B |
Dividend Yield | 3.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.88, down 0.61% on the day, with a neutral technical signal despite bullish moving averages. The company reported Q2 2026 EPS of $0.79, beating estimates, driven by 21% APE sales growth in Asia. Revenue reached $53.01B in 2025, with net income margin at 11.7%. Recent news highlights AI partnerships with Microsoft and Alibaba Cloud, enhancing operational efficiency.
Outlook is positive with 57% analyst buy ratings and a $51.50 consensus target, though premium valuation (P/E 16.57) and mixed earnings history pose risks. Strengths include robust cash flow and dividend consistency, but investors face headwinds from competitive pressures and regulatory scrutiny in Asian markets.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
